Abstract | BACKGROUND: Medical treatment with trilostane improves clinical signs, causes unclear insulin requirement changes, and variable survival times in cats. OBJECTIVES/HYPOTHESIS: ANIMALS: Fifteen client-owned cats with spontaneous HAC. METHODS: Multicenter descriptive retrospective study with a search performed on all medical records for cats diagnosed with spontaneous HAC. RESULTS: CONCLUSIONS AND CLINICAL IMPORTANCE:
Trilostane ameliorates clinical signs of HAC in cats, is tolerated well in the long term, and can lead to improved regulation of diabetes.
|
Authors | A M Mellett Keith, D Bruyette, S Stanley |
Journal | Journal of veterinary internal medicine
(J Vet Intern Med)
2013 Nov-Dec
Vol. 27
Issue 6
Pg. 1471-7
ISSN: 1939-1676 [Electronic] United States |
PMID | 24011349
(Publication Type: Journal Article, Multicenter Study)
|
Copyright | Copyright © 2013 by the American College of Veterinary Internal Medicine. |
Chemical References |
- Enzyme Inhibitors
- Insulin
- Dihydrotestosterone
- trilostane
|
Topics |
- Adrenocortical Hyperfunction
(diagnostic imaging, drug therapy, physiopathology, veterinary)
- Animals
- Body Weight
(physiology)
- Cat Diseases
(diagnostic imaging, drug therapy, physiopathology)
- Cats
- Diabetes Mellitus
(physiopathology, veterinary)
- Dihydrotestosterone
(analogs & derivatives, pharmacology, therapeutic use)
- Enzyme Inhibitors
(pharmacology, therapeutic use)
- Female
- Insulin
(administration & dosage)
- Male
- Retrospective Studies
- Ultrasonography
|